Genentech Inc - Articles and news items

FDA approves chronic lymphocytic leukaemia drug Venclexta

Industry news / 12 April 2016 / Victoria White, Digital Content Producer

Venclexta is the first FDA-approved treatment that targets the BCL-2 protein, which supports cancer cell growth and is overexpressed in many CLL patients…

Rituxan

FDA approves Rituxan plus a steroid for use in severe forms of vasculitis

Industry news, News / 19 April 2011 / Biogen Idec

Genentech, and Biogen Idec announced today that the FDA approved Rituxan® (rituximab)…

Genentech’s ECP-1 Bacterial Manufacturing Facility Named 2010 Facility of the Year Awards Overall Winner

Industry news, News / 8 November 2010 / ISPE

ISPE, announced that Genentech’s ECP-1 Bacterial Manufacturing Facility is the overall winner…

Is the dream becoming reality?

Issue 6 2006, Past issues / 28 November 2006 / Andy Chang and Jean-Philippe Stephan Ph.D., Assay and Automation Technology department, Genentech, Inc

During the last decade, technical developments have dramatically changed the way cell-based assays could be implemented and used in research and development organisations. Although cell-based assays have moved into a modern era, cells are still grown and maintained in the same way as decades ago; i.e. manually. However, automation systems with the ability to grow and maintain cells have emerged, bringing us closer to the dream of fully automated cell culture.

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+